We keep you up-to-date about the happenings on the field of PH and rare diseases and provide you with healthcare-related news in the European Union and beyond.
Proceedings from the 7th World PH Symposium is Now Published
I am thrilled to share that the proceedings from Task Force 1 (Patient Perspective) at the 7th World Pulmonary Hypertension Symposium (WPHS) have been published in the European Respiratory Journal (ERJ).
EMA Approves WINREVAIR (Sotatercept) for Treatment of PAH
PHA Europe is pleased to share the exciting news that the European Medicines Agency (EMA) has approved WINREVAIR™ (sotatercept) for the treatment of Pulmonary Arterial Hypertension (PAH).
Report from the International PHA conference
PHA recently held its 15th international PH conference in Indianapolis, Indiana. This gathering brought together a diverse group of about 1100 healthcare professionals, researchers, patients, and advocates from around the world, all united by a shared commitment to advancing the understanding and treatment of pulmonary hypertension.
World’s 7th PH Symposium
I had the honor of representing PHA Europe at the World Symposium for Pulmonary Hypertension (PH) in Barcelona, held from June 28th until July 1st.
TORREY results in Lancet
The pharmaceutical company Gossamer Bio, celebrates a significant achievement with the publication of its TORREY Phase 2 study results in the esteemed Lancet Respiratory Medicine journal.
Report from IMPAHCT 2024
Approximately 150 pulmonary hypertension (PH) specialists convened in Barcelona in April 2024 for Ferrer’s 6th edition of the IMPAHCT meeting. Notably, Hall Skaara represented PHA Europe for the second time at the conference, serving as the sole patient advocate present.
Report from EPF’s AGM – Brussels 13th and 14 of April 2024
The European Patient Forum (EPF) recently convened its Annual General Meeting (AGM) in Brussels, inviting its full members to participate. The two-day event began with a focus on Artificial Intelligence (AI) on day one, followed by the official AGM proceedings on day two.
FDA recently approved Opsynvi
The FDA recently approved Opsynvi, developed by Johnson & Johnson, for treating pulmonary arterial hypertension (PAH) in adults, marking a significant advancement in PAH management.
Sotatercept approved by FDA
Merck, also known as MSD outside of the United States and Canada, has announced the FDA approval of Winrevair™ (sotatercept), a groundbreaking biologic for the treatment of adults with pulmonary arterial hypertension (PAH).